Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 April 1991Website:
http://www.regeneron.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
REGN Latest News
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
What type of business is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes drugs for the treatment of various diseases - eye diseases, allergies, infections, cardiovascular diseases, metabolic diseases, inflammatory diseases, oncology, and other rare diseases. The company was founded in 1988, with headquarters located in Tarrytown, New York. Currently, Regeneron has seven products that have received marketing approval and are sold in collaboration with Bayer and Sanofi (based on licensing agreements).
What sector is Regeneron Pharmaceuticals in?
Regeneron Pharmaceuticals is in the Healthcare sector
What industry is Regeneron Pharmaceuticals in?
Regeneron Pharmaceuticals is in the Biotechnology industry
What country is Regeneron Pharmaceuticals from?
Regeneron Pharmaceuticals is headquartered in United States
When did Regeneron Pharmaceuticals go public?
Regeneron Pharmaceuticals initial public offering (IPO) was on 02 April 1991
What is Regeneron Pharmaceuticals website?
https://www.regeneron.com
Is Regeneron Pharmaceuticals in the S&P 500?
Yes, Regeneron Pharmaceuticals is included in the S&P 500 index
Is Regeneron Pharmaceuticals in the NASDAQ 100?
Yes, Regeneron Pharmaceuticals is included in the NASDAQ 100 index
Is Regeneron Pharmaceuticals in the Dow Jones?
No, Regeneron Pharmaceuticals is not included in the Dow Jones index
When does Regeneron Pharmaceuticals report earnings?
The next expected earnings date for Regeneron Pharmaceuticals is 02 August 2024